ArticleJournal of the advanced practitioner in oncology2025
Improving Use of Cytomegalovirus Negative and Irradiated Blood Products in an Outpatient Oncology Clinic.
Article in Journal of the advanced practitioner in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Indications for the use of cytomegalovirus (CMV)-neg-ative and irradiated blood products (IRBP) are not standardized and are often poorly understood by providers. This project evaluated the use of a transfusion algorithm in an outpatient oncology clinic to reduce the risk of transfusion-associated graft-vs.-host disease (TA-GVHD) and eliminate the improper use of CMV-negative and irradiated blood products. Objectives: The aim of this project was to increase the correct use of CMV-negative and irradiated blood products at an outpatient oncology clinic by establishing a transfusion algorithm, to evaluate the effectiveness of clinical transfusion algorithms on the use of specialty blood products, and to educate providers on TA-GVHD. Methods: This quasi-experimental project compared 12 weeks of transfusion data before the implementation of a transfusion algorithm to 12 weeks of transfusion data after the algorithm was introduced. A preand post-test survey measured the satisfaction and the impact of the education. Findings: The transfusion algorithm resulted in a clinically significant increase in the correct use of both CMV-negative and irradiated blood products at an outpatient oncology clinic. The education in-services provided to staff about TA-GVHD and the indications for irradiated blood product resulted in a significant increase in provider knowledge on ordering specialty blood products.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.